GoodCap Pharmaceuticals Inc.

GoodCap Pharmaceuticals Inc. (goodcapwellness.com) is a leading Canadian drug development and retail experience company devoted to harnessing and applying the physical and mental health benefits of mushrooms and mushroom-derived compounds.

Recent News

GoodCap Pharmaceuticals Announces Publication of Positive Results from Two Studies Relating to GoodCap's Lead Drug Candidate
Toronto, Ontario--(Newsfile Corp. - September 12, 2023) - GoodCap Pharmaceuticals Inc. ("GoodCap" or the "Company"), a leading biopharmaceutical company focused on discovering and developing novel anti-inflammatory treatments for mood-disorders, today announced the publication of two manuscripts. These studies explore groundbreaking approaches to treating the broad symptomology associated with Post-Traumatic Stress Disorder (PTSD) by targeting the underlying factors of chronic inflammation and oxidative stress. Links to the manuscripts can be found here: https://www.mdpi.com/1420-3049/28/6/2624https://www.mdpi.com/1467-3045/45/8/427
2023-09-12 9:00 AM EDT
GoodCap Announces the Appointment of Dr. Laura Targownik to Its Scientific Advisory Board
Toronto, Ontario--(Newsfile Corp. - January 17, 2023) - GoodCap Pharmaceuticals Inc. ("GoodCap" or the "Company"), is pleased to announce the appointment of Dr. Laura Targownik, MD, to its Scientific Advisory Board.Dr. Targownik is currently a Clinician Researcher in the Mount Sinai Hospital Inflammatory Bowel Disease Clinic and is a member of the Zane Cohen Centre for Gastrointestinal Research. She is also the Director for the University of Toronto Division of Gastroenterology and Hepatology and is a faculty member of the...
2023-01-17 9:00 AM EST
GoodCap Pharmaceuticals and the University of Toronto Awarded NSERC Alliance Grant for Ongoing Research of Low-Dose Psilocybin Drug Formulas Targeting Inflammation and Depressive Disorders
Toronto, Ontario--(Newsfile Corp. - November 10, 2022) - GoodCap Pharmaceuticals Inc. ("GoodCap" or the "Company"), a biopharmaceutical company developing low-dose psychedelic therapies, is pleased to announce that the Natural Sciences and Engineering Research Council of Canada (NSERC) has awarded an Alliance Grant to its research partner at the University of Toronto (the "University") for $237,339, effective October 2022 to be paid through 2023. The research is focused on furthering the evaluation and development of GoodCap's combination therapies designed to...
2022-11-10 10:00 AM EST
GoodCap Pharmaceuticals Announces Publication of International Patent Application
Toronto, Ontario--(Newsfile Corp. - June 30, 2022) - GoodCap Pharmaceuticals Inc. ("GoodCap"), a biopharmaceutical company developing low-dose psychedelic therapies, is pleased to announce publication of its international patent application (PCT/IB2021/059301) (the "Patent"). The Patent covers the administration of 5HT2A receptor agonists, which include psychedelic molecules, combined with potentiator molecules, to target chronic inflammatory markers, which are believed to be a significant contributor to Treatment Resistant Depression. Under this Patent, GoodCap expects to obtain significant formulation and method-of-use protection for...
2022-06-30 9:00 AM EDT

GoodCap Pharmaceuticals Inc.

Recent News

Get News by Email

RSS Feeds

Regulatory Filings

Tell Us Your Story

Cookie Settings

Get News by Email

RSS Feeds

Regulatory Filings

Tell Us Your Story